Filing summary
Entity and period mismatch: The supplied filing is for Desert Gateway, Inc., not Travere Therapeutics, Inc. It is a Form 10-K for the fiscal year ended February 29, 2012, rather than a filing identified as 2011 Q4. The summary below reflects the filing text provided.
Business context
Desert Gateway describes itself as a shell company with no meaningful operations, assets beyond cash, or revenue. Its stated purpose is to locate and complete a merger or acquisition; it had identified no target and had no related agreement or discussions. The common stock traded on the Pink Sheets under DGTE, with no active trading reported for approximately three years.
Financial results and liquidity
| Metric | Year ended Feb. 29, 2012 | Year ended Feb. 28, 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $12,825 | $12,689 |
| Interest and debt-discount amortization | $2,000 | $10,333 |
| Net loss | $14,825 | $23,022 |
| Cash used in operating activities | $49 | $689 |
At February 29, 2012, cash and total assets were $3,909; current liabilities were $66,989, producing negative working capital of $63,080. Stockholders’ deficit was $63,080 and accumulated deficit was $136,081. Liabilities included a $25,000 convertible note, $25,000 accrued professional fees, $6,667 accrued interest, $9,572 due to related parties, and $750 accounts payable. No meaningful margin measure is applicable because the company had no revenue.
The $25,000 note bears 8% annual interest, is convertible at the holder’s option at $0.01 per share, and matures November 1, 2012. The filing says operations depend on funding from stockholders, management, or other investors. It reports no off-balance-sheet transactions.
Changes, outlook, and risks
- Net loss narrowed by $8,197 year over year, primarily as reported interest and debt-discount expense declined; operating expenses were broadly stable. Cash declined by $49 during fiscal 2012.
- Management anticipated costs for SEC reporting and a potential acquisition over the next 12 months, funded from treasury cash and possible loans or investments. No financing commitment or acquisition candidate was disclosed.
- The auditor issued an unmodified opinion on the financial statements but included a going-concern paragraph, citing cumulative losses and doubt about resources to fund operations through February 28, 2013. The statements include no adjustments for a possible failure to continue as a going concern.
- Management disclosed material weaknesses in financial reporting controls, including inadequate segregation of duties, lack of accounting expertise and no independent directors or audit committee. The auditor did not attest to internal control effectiveness.
- Principal risks include insolvency and inability to raise funds, failure to identify or complete a business combination, competition for targets, substantial dilution and potential change of control, limited management availability, and illiquidity of the stock. A combination may be concentrated in a single business and may require audited target financial statements.
- The company reported approximately $136,000 of accumulated net operating losses, but stated that $60,000 was available for carryforward; realization is uncertain and substantially offset by a valuation allowance. Use may be limited following a change in control.
Important facts to verify
- Confirm the intended issuer and reporting period: the supplied document names Desert Gateway, Inc., not Travere Therapeutics, Inc.
- Reconcile share-count disclosures: the filing reports 95,910,983 common shares outstanding at February 29, 2012, but its balance sheet and other passages show 106,681; it also describes a reverse split.
- Verify preferred shares outstanding: the balance sheet lists 501, while other filing disclosures state that none were outstanding.
- Confirm the note’s maturity and current status, given the November 1, 2012 maturity date and the filing’s going-concern warning.
- Review the disclosed control weaknesses and the inconsistencies in the control-evaluation dates and share-count information before relying on reported data.